Zicam Settles False Advertising Class Action for $16 Million

The makers of the cold and allergy medication Zicam have agreed to pay a $16 million settlement to resolve a class action lawsuit. According to the lawsuit, Zicam made “false and misleading statements about the effectiveness of certain Zicam products in violation of state and federal law.” Zicam is denying these claims.

Consumers who bought certain Zicam products between February 15, 2011 and June 5, 2018 can file a claim on their website to receive a cash payment. The following Zicam products are eligible:

RapidMelts Original
RapidMelts Ultra
Oral Mist
Ultra Crystals
Lozenges Ultra

Consumers can file up to five claims for those products without a receipt. However, with proof of purchase consumers are not limited on the amount of claims they file. Proof of purchase includes receipts, package, bottles or containers.

Claims can be filed here. The deadline to file a claim is October 3, 2018.

This blog is intended to provide information to the general public and to practitioners about developments that may impact Oregon class actions.

Sign up to receive Class Actions Blog posts in your inbox!

Steve Larson
An experienced trial lawyer who handles both hourly and contingent fee cases, Steve has expertise in class actions, antitrust litigation, securities litigation, corporate disputes, intellectual property disputes, unfair competition claims, and disputes involving family wealth. Steve regularly represents individuals and businesses in federal and state court and has obtained class-wide recovery in multiple class actions. A veteran practitioner, Steve's clients value his creative approach to resolving complex litigation matters.


Share on facebook
Share on twitter
Share on google
Share on linkedin

Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.